Literature DB >> 20609353

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Marta Puyol1, Alberto Martín, Pierre Dubus, Francisca Mulero, Pilar Pizcueta, Gulfaraz Khan, Carmen Guerra, David Santamaría, Mariano Barbacid.   

Abstract

We have unveiled a synthetic lethal interaction between K-Ras oncogenes and Cdk4 in a mouse tumor model that closely recapitulates human non-small cell lung carcinoma (NSCLC). Ablation of Cdk4, but not Cdk2 or Cdk6, induces an immediate senescence response only in lung cells that express an endogenous K-Ras oncogene. No such response occurs in lungs expressing a single Cdk4 allele or in other K-Ras-expressing tissues. More importantly, targeting Cdk4 alleles in advanced tumors detectable by computed tomography scanning also induces senescence and prevents tumor progression. These observations suggest that robust and selective pharmacological inhibition of Cdk4 may provide therapeutic benefit for NSCLC patients carrying K-RAS oncogenes. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609353     DOI: 10.1016/j.ccr.2010.05.025

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  199 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Authors:  Rafael B Blasco; Sarah Francoz; David Santamaría; Marta Cañamero; Pierre Dubus; Jean Charron; Manuela Baccarini; Mariano Barbacid
Journal:  Cancer Cell       Date:  2011-04-21       Impact factor: 31.743

3.  Therapy: Lethal cycling.

Authors:  Darren J Burgess
Journal:  Nat Rev Cancer       Date:  2010-09       Impact factor: 60.716

4.  Cancer: Lethal cycling.

Authors:  Darren J Burgess
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

Review 5.  The essence of senescence.

Authors:  Thomas Kuilman; Chrysiis Michaloglou; Wolter J Mooi; Daniel S Peeper
Journal:  Genes Dev       Date:  2010-11-15       Impact factor: 11.361

6.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Authors:  Patrick J Roberts; John E Bisi; Jay C Strum; Austin J Combest; David B Darr; Jerry E Usary; William C Zamboni; Kwok-Kin Wong; Charles M Perou; Norman E Sharpless
Journal:  J Natl Cancer Inst       Date:  2012-02-01       Impact factor: 13.506

Review 7.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

8.  Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progression.

Authors:  Sharad S Singhal; James Figarola; Jyotsana Singhal; Lokesh Nagaprashantha; David Berz; Samuel Rahbar; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

9.  The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.

Authors:  Sabine Paternot; Bianca Colleoni; Xavier Bisteau; Pierre P Roger
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Authors:  Miriam Molina-Arcas; David C Hancock; Clare Sheridan; Madhu S Kumar; Julian Downward
Journal:  Cancer Discov       Date:  2013-03-01       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.